DrugPatentWatch Database Preview
Gemini Labs Llc Company Profile
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the competitive landscape for GEMINI LABS LLC, and what generic and branded alternatives to GEMINI LABS LLC drugs are available?
GEMINI LABS LLC has two approved drugs.
Summary for Gemini Labs Llc
| US Patents: | 0 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Gemini Labs Llc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gemini Labs Llc | OXANDRIN | oxandrolone | TABLET;ORAL | 013718-002 | Nov 5, 2001 | DISCN | Yes | No | Start Trial | Start Trial | |||||
| Gemini Labs Llc | PRANDIN | repaglinide | TABLET;ORAL | 020741-002 | Dec 22, 1997 | DISCN | Yes | No | Start Trial | Start Trial | |||||
| Gemini Labs Llc | PRANDIN | repaglinide | TABLET;ORAL | 020741-001 | Dec 22, 1997 | DISCN | Yes | No | Start Trial | Start Trial | |||||
| Gemini Labs Llc | OXANDRIN | oxandrolone | TABLET;ORAL | 013718-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | Start Trial | Start Trial | |||||
| Gemini Labs Llc | PRANDIN | repaglinide | TABLET;ORAL | 020741-003 | Dec 22, 1997 | DISCN | Yes | No | Start Trial | Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Gemini Labs Llc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Gemini Labs Llc | PRANDIN | repaglinide | TABLET;ORAL | 020741-002 | Dec 22, 1997 | 5,216,167 | Start Trial |
| Gemini Labs Llc | PRANDIN | repaglinide | TABLET;ORAL | 020741-002 | Dec 22, 1997 | 4,873,080 | Start Trial |
| Gemini Labs Llc | OXANDRIN | oxandrolone | TABLET;ORAL | 013718-002 | Nov 5, 2001 | 6,090,799 | Start Trial |
| Gemini Labs Llc | PRANDIN | repaglinide | TABLET;ORAL | 020741-002 | Dec 22, 1997 | 6,143,769 | Start Trial |
| Gemini Labs Llc | PRANDIN | repaglinide | TABLET;ORAL | 020741-001 | Dec 22, 1997 | 6,677,358 | Start Trial |
| Gemini Labs Llc | PRANDIN | repaglinide | TABLET;ORAL | 020741-001 | Dec 22, 1997 | 5,216,167 | Start Trial |
| Gemini Labs Llc | OXANDRIN | oxandrolone | TABLET;ORAL | 013718-001 | Approved Prior to Jan 1, 1982 | 5,872,147 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for GEMINI LABS LLC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 2.5 mg and 10 mg | ➤ Subscribe | 2006-06-19 |
| ➤ Subscribe | Tablets | 0.5 mg, 1 mg and 2 mg | ➤ Subscribe | 2005-02-10 |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
